YCT529
Chemical compound
Identifiers | |
---|---|
| |
PubChem CID |
|
UNII |
|
Chemical and physical data | |
Formula | C29H25NO3 |
Molar mass | 435.523 g·mol−1 |
3D model (JSmol) |
|
| |
InChI
|
YCT529 is a drug which acts as a potent and selective antagonist of the Vitamin A receptor retinoic acid receptor alpha (RAR-α). In studies on mice it produced a 99% reduction in sperm production, and it has proceeded to early stage human clinical trials as a potential male contraceptive.[1]
The Vitamin A signalling system plays a number of important roles in bodily systems, such as the Immune system “It seems to me inherently unlikely that a compound with such activity would be free of side effects,” says Richard Sharpe, of the University of Edinburgh.[2]
See also
- Adjudin
- CDD-2807
- Dimethandrolone undecanoate
- JQ1
- TDI-11861